Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

An Observational Study of Herceptin SC Safety in Breast Cancer
An Observational Study of Herceptin SC Safety in Breast Cancer

NCT02305628

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Breast Cancer

Countries: South Korea

This is a phase IV, prospective, multicenter, observational study (regulatory post-marketing surveillance) in approximately 600 patients who are to receive Herceptin SC (trastuzumab, subcutaneous administration) per approved local labeling. Patients will be under observation according to standard of care in Korea.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

\- All patients administered Herceptin SC for the locally approved indications

Exclusion Criteria:

N/A
Locations (23)
  • Busan, South Korea
  • Busan, South Korea
  • Daegu, South Korea
  • Gyeonggi-do, South Korea
  • Gyeonggi-do, South Korea
  • Gyeonggi-do, South Korea
  • Gyeongsangnam-do, South Korea
  • Gyeongsangnam-do, South Korea
  • Incheon, South Korea
  • Incheon, South Korea
  • Jeollanam-do, South Korea
  • Jeonlabuk-do, South Korea
  • Seoul, South Korea
  • Seoul, South Korea
  • Seoul, South Korea
  • Seoul, South Korea
  • Seoul, South Korea
  • Seoul, South Korea
  • Seoul, South Korea
  • Seoul, South Korea
  • Seoul, South Korea
  • Seoul, South Korea
  • Ulsan, South Korea